Tel Aviv University

Julia Leitman

Daniel Offen

Moshe Portnoy

Gerardo Zelmar Lederkremer

Javier Ganz

Hagit Eiger

Compounds represented by Formula I are disclosed herein,  wherein R, Ra and R-Rare as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

Compounds represented by Formula I are disclosed herein, wherein R, Ra and R-Rare as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

Growing community of inventors

Petach-Tikva, Israel

Julia Leitman